Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Preferred Stock Liabilities: 2015-2024

Historic Preferred Stock Liabilities for Spyre Therapeutics (SYRE) over the last 1 years, with Mar 2024 value amounting to $253.4 million.

  • Spyre Therapeutics' Preferred Stock Liabilities was N/A to $253.4 million in Q1 2024 from the same period last year, while for Mar 2024 it was $253.4 million, marking a year-over-year change of. This contributed to the annual value of $84.6 million for FY2023, which is N/A change from last year.
  • Latest data reveals that Spyre Therapeutics reported Preferred Stock Liabilities of $253.4 million as of Q1 2024, which was up 199.69% from $84.6 million recorded in Q4 2023.
  • In the past 5 years, Spyre Therapeutics' Preferred Stock Liabilities registered a high of $387.1 million during Q3 2023, and its lowest value of $84.6 million during Q4 2023.
  • Its 2-year average for Preferred Stock Liabilities is $230.6 million, with a median of $225.4 million in 2023.